Rachel Tsunemoto Hislop
Directeur/Membre du Conseil chez Abilita Therapeutics, Inc.
Profil
Rachel Tsunemoto Hislop is currently working as a Director at Abilita Therapeutics, Inc. and as a Principal at Two Bear Capital Operations LLC since 2020.
She completed her undergraduate degree from Massachusetts Institute of Technology.
Postes actifs de Rachel Tsunemoto Hislop
| Sociétés | Poste | Début |
|---|---|---|
Two Bear Capital Operations LLC
 Two Bear Capital Operations LLC Investment ManagersFinance Two Bear Capital Operations LLC (Two Bear Capital) is venture capital firm founded in 2019 by Mike Goguen. The firm is headquartered in Whitefish, Montana. | Private Equity Investor | 01/01/2020 |
Abilita Therapeutics, Inc.
 Abilita Therapeutics, Inc. BiotechnologyHealth Technology Abilita Therapeutics, Inc. is a biotechnology company that focuses on discovering and developing drugs that target challenging human membrane proteins with high medical impact, such as GPCRs, ion channels, and transporters. The company is based in San Diego, CA. The company's internal drug discovery pipeline is focused on treating cancer and chronic pain. Abilita Bios EMP™ platform fuels research collaborations with pharmaceutical and biotech partners. The company was founded in 2014 by Mauro Mileni, who has been the CEO since 2014. | Directeur/Membre du Conseil | - |
Formation de Rachel Tsunemoto Hislop
| Massachusetts Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Two Bear Capital Operations LLC
Two Bear Capital Operations LLC Investment ManagersFinance Two Bear Capital Operations LLC (Two Bear Capital) is venture capital firm founded in 2019 by Mike Goguen. The firm is headquartered in Whitefish, Montana. | Finance |
Abilita Therapeutics, Inc.
Abilita Therapeutics, Inc. BiotechnologyHealth Technology Abilita Therapeutics, Inc. is a biotechnology company that focuses on discovering and developing drugs that target challenging human membrane proteins with high medical impact, such as GPCRs, ion channels, and transporters. The company is based in San Diego, CA. The company's internal drug discovery pipeline is focused on treating cancer and chronic pain. Abilita Bios EMP™ platform fuels research collaborations with pharmaceutical and biotech partners. The company was founded in 2014 by Mauro Mileni, who has been the CEO since 2014. | Health Technology |